Navigation Links
OcumatRx Announces Promising Clinical Trial Results for Implant with Potential to Permanently Treat Glaucoma
Date:8/12/2009

CaPRI implant achieves significant drop in intraocular pressure; company advances to next generation of device, new trials

San Diego, CA (PRWEB) August 12, 2009 -- OcumatRx, an early stage company that is developing a medical device that represents a new concept for the permanent treatment of patients with Glaucoma, has announced the successful completion of clinical trials for their first device with favorable preliminary safety and tolerability. As a result, the company is now moving forward with a more sophisticated design of the device, with plans to launch new clinical trials later this year.

Dr. Bernard Press, president of OcumatRx, said that after years of research and development, the CaPRI device, named after its inventor, Dr. David Castillejos, ophthalmologist, who pioneered the pressure reduction implant (PRI) technology, showed significant results in lowering intraocular pressures during recent trials conducted in Mexico. During the trials involving 10 patients aged from 40 to 75, the first generation of the CaPRI device was inserted into one eye and the other eye was used as the control.

Press said the subjects were tested over a 12 month period and at the end of the trial the average drop in pressure was 6.4 millimeters, an achievement which is better than the current standard of care for increased intraocular pressure, which is using prescription drops.

"We are encouraged by the early results and are now finalizing the next generation of the device, designed by Dr. Castillejos after further research and development," said Press. "For glaucoma patients, having a permanent implant has the potential to stabilize pressure without the need for expensive drops, which can lose efficacy over time."

The CaPRI is inserted in a minimally invasive procedure, stabilizes intra-ocular pressure and stops the progression of Glaucoma in the ear
'/>"/>

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Preferred Health Technology Announces Support for MGMAs Project SwipeIT
2. International Isotopes Inc. Announces Second Quarter and Six Months 2009 Financial Results
3. Fountain Healthy Aging Inc Announces $5,000,000 Equity Line Of Credit Investment Secured
4. Endo Pharmaceuticals Announces Resignation of Chief Operating Officer
5. Beckman Coulter Announces the Creation of Beckman Coulter Genomics
6. The Brain Aneurysm Foundation Announces Six Grants to Further Treatment for Brain Aneurysms
7. Schering-Plough Announces Resolution of Litigations on U.S. Marketing of Generic Forms of Solid Oral Dosage Forms of CLARINEX(R)
8. 3SBio Inc. Announces Unaudited Second Quarter 2009 Results
9. Jazz Pharmaceuticals Announces Second Quarter 2009 Financial Results
10. Webmedx Announces That CEO Sean Carroll Has Been Appointed to the AHIMA Foundation Board of Directors
11. Epix Pharmaceuticals, Inc. Announces PRX-07034 Therapeutics - CNS Phase 2 Will be Part of the Intellectual Property Offered for Sale at the September 30, 2009 Auction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... Science published an article about bexarotene as a ... starting point for further Alzheimer,s research. The research group ... and KU Leuven in collaboration with the group ... at Janssen Pharmaceutica, Beerse, also tested this candidate drug ... different, as were those of two American study groups. ...
(Date:5/23/2013)... being dragged to its destruction inside a cell, ... signals that thwart the development of tumor-suppressing microRNAs ... early online publication at Nature . , ... tumors, the epidermal growth factor receptor (EGFR) gums ... led by scientists at The University of Texas ...
(Date:5/23/2013)... 23, 2013 The Rottenstein Law Group ... has created the Tylenol Lawsuit Information Center at ... users and those who are considering filing lawsuits. ... potentially cause severe liver damage, according to a 2009 ... In the “safety communication,” the FDA warned consumers against ...
(Date:5/23/2013)... DC (PRWEB) May 23, 2013 The ... a great deal of control over their level of ... weight, yet far fewer are actually taking that control. ... Food Information Council (IFIC) Foundation’s 2013 Food & Health ... respondents say it’s possible to have “a great deal ...
(Date:5/23/2013)... Jeanne Ettelson, president of Beyond OCD , ... free OCD support group in Chicago. Launched in ... the group is lead by psychologists who specialize in ... group participants to learn accurate information about OCD, Cognitive ... in Beyond OCD’s support group benefit from being ...
Breaking Medicine News(10 mins):Health News:New insights contradict promising Alzheimer's research 2Health News:When oxygen is short, EGFR prevents maturation of cancer-fighting miRNAs 2Health News:When oxygen is short, EGFR prevents maturation of cancer-fighting miRNAs 3Health News:Rottenstein Law Group LLP Now Accepting Tylenol Cases, Announces New Tylenol Lawsuit Information Center 2Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 2Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 3Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 4Health News:Beyond OCD Support Group Marks Fifth Anniversary 2
... by youngsters with the disease , THURSDAY, July 2 (HealthDay ... to be overweight than those without the disease, increasing their ... is from a major study that explored the weight problems ... common form of the disease that usually shows up in ...
... the launch of (RED)ZONES at the first U2 360 Degrees concert ... rapturous sold out crowd of 90,000 fans. , , ... will be present throughout the U2 tour. The tickets for ... the ticket sales going to the Global Fund to help fund ...
... reports of DEA intervention are accurate, Michael Jackson,s doctors will ... won,t end there. The pharmacists who filled Mr. Jackson,s prescriptions ... name is associated with any of Jackson,s prescriptions," said attorney ... won full federal jury acquittal at trial on a 10 ...
... Cardinal Health today announced that Bruce L. Downey will ... of the planned spinoff of CareFusion Corporation, replacing John B. ... after 22 years of service to the company as a ... chairman and chief executive officer of Barr Pharmaceuticals, Inc. and ...
... the advisory committee,s recommendations to the U.S. Food and Drug Administration (FDA) ... physician leaders from the American Academy of Pain Medicine ... The American Academy of Pain Medicine ... specialty of Pain Medicine, supports the safe and responsible, ...
... the pipeline, could plug a Percocet-Vicodin gap, experts say, , ... Percocet and Vicodin, which a U.S. health advisory panel has ... medical experts contend. , The reason, they say, is that ... Administration advisory panel made its recommendation Tuesday. It followed the ...
Cached Medicine News:Health News:Kids With Type 1 Diabetes Often Overweight 2Health News:(RED)ZONES Launch at First U2 360 Degrees Concert in Barcelona 2Health News:(RED)ZONES Launch at First U2 360 Degrees Concert in Barcelona 3Health News:DEA Will Play Hardball in Investigating Michael Jackson's Doctors 2Health News:Cardinal Health Appoints Bruce Downey to Board of Directors; John McCoy Retires From Board After 22 Years 2Health News:Pain Medicine Experts Recommend Safe and Responsible Use of Acetaminophen 2Health News:If 2 Painkillers Are Banned, What Next? 2Health News:If 2 Painkillers Are Banned, What Next? 3Health News:If 2 Painkillers Are Banned, What Next? 4
(Date:5/23/2013)... May 23, 2013  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: ... named the 2013 Life Science Firm of the Year by ... Vanda was honored at the TCM,s 25 th Annual ... Maryland.  The Tech Awards Celebration recognizes the leaders and innovators ... Maryland and the surrounding regions. ...
(Date:5/23/2013)... de mayo de 2013  Volcano Corporation (NASDAQ: ... fabricante de herramientas de precisión para terapia guiadas ... la enfermedad vascular periférica y coronaria, anunció hoy ... enosine V asodilator I ndependent ... sesión de ensayo clínico hot line late breaking ...
(Date:5/23/2013)... Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) ... and Chief Executive Officer of Neurocrine Biosciences, will be presenting ... Care Conference in Boston.   The live presentation ... Time / 8:20 a.m. Pacific Time.  The presentation will be ... http://www.neurocrine.com . If you are unable ...
Breaking Medicine Technology:Vanda Pharmaceuticals Named the 2013 Life Science Firm of the Year by the Tech Council of Maryland 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 3Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 4Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 5Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 6
... (CRL) has invested in a low-dose, state-of-the-art CT machine ... Minnesota.  This advanced diagnostic system will help physicians reach ... care with a radiation dose up to 40% lower ... "The addition of the GE Healthcare Brightspeed Elite CT ...
... ECRI Institute ®, an independent ... improving patient care, today announces the launch of its ... to ECRI Institute,s SELECTplus™ healthcare technology advisory service. The ... intelligence to help hospitals and health systems select and ...
Cached Medicine Technology:Consulting Radiologists, Ltd. Announces Addition of a Low Dose Advanced Computed Tomography (CT) System 2ECRI Institute Launches Market Analytics Tool to Help Hospitals Make More Informed Capital Purchasing Decisions 2ECRI Institute Launches Market Analytics Tool to Help Hospitals Make More Informed Capital Purchasing Decisions 3
40-well gradient cycler...
... a high quality, compact thermal cycler. In addition ... Mastercycler personal offers first-rate operational flexibility. Its universal ... x 0.2 ml tubes, 16 x 0.5 ml ... grid format. Like the Mastercycler and the Mastercycler ...
... instrument and custom filter wheels with ... The standard filter set includes: FAM/SYBR ... Red (585nm-610nm), Cy5 (635nm-665nm) and Cy3 ... Mx3005P analysis software, Beacon Designer oligo ...
... The system includes: Mx3005P instrument and ... of five (5) filters. The standard ... (492nm-516nm), HEX/JOE/VIC (535nm-555nm), ROX/Texas Red (585nm-610nm), ... included: desktop computer, Mx3005P analysis software, ...
Medicine Products: